Cargando…

Novel viral vectors in infectious diseases

Since the development of vaccinia virus as a vaccine vector in 1984, the utility of numerous viruses in vaccination strategies has been explored. In recent years, key improvements to existing vectors such as those based on adenovirus have led to significant improvements in immunogenicity and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Humphreys, Ian R., Sebastian, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721250/
https://www.ncbi.nlm.nih.gov/pubmed/28869761
http://dx.doi.org/10.1111/imm.12829
_version_ 1783284771875454976
author Humphreys, Ian R.
Sebastian, Sarah
author_facet Humphreys, Ian R.
Sebastian, Sarah
author_sort Humphreys, Ian R.
collection PubMed
description Since the development of vaccinia virus as a vaccine vector in 1984, the utility of numerous viruses in vaccination strategies has been explored. In recent years, key improvements to existing vectors such as those based on adenovirus have led to significant improvements in immunogenicity and efficacy. Furthermore, exciting new vectors that exploit viruses such as cytomegalovirus (CMV) and vesicular stomatitis virus (VSV) have emerged. Herein, we summarize these recent developments in viral vector technologies, focusing on novel vectors based on CMV, VSV, measles and modified adenovirus. We discuss the potential utility of these exciting approaches in eliciting protection against infectious diseases.
format Online
Article
Text
id pubmed-5721250
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57212502017-12-12 Novel viral vectors in infectious diseases Humphreys, Ian R. Sebastian, Sarah Immunology Review Articles Since the development of vaccinia virus as a vaccine vector in 1984, the utility of numerous viruses in vaccination strategies has been explored. In recent years, key improvements to existing vectors such as those based on adenovirus have led to significant improvements in immunogenicity and efficacy. Furthermore, exciting new vectors that exploit viruses such as cytomegalovirus (CMV) and vesicular stomatitis virus (VSV) have emerged. Herein, we summarize these recent developments in viral vector technologies, focusing on novel vectors based on CMV, VSV, measles and modified adenovirus. We discuss the potential utility of these exciting approaches in eliciting protection against infectious diseases. John Wiley and Sons Inc. 2017-09-26 2018-01 /pmc/articles/PMC5721250/ /pubmed/28869761 http://dx.doi.org/10.1111/imm.12829 Text en © 2017 The Authors. Immunology Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Humphreys, Ian R.
Sebastian, Sarah
Novel viral vectors in infectious diseases
title Novel viral vectors in infectious diseases
title_full Novel viral vectors in infectious diseases
title_fullStr Novel viral vectors in infectious diseases
title_full_unstemmed Novel viral vectors in infectious diseases
title_short Novel viral vectors in infectious diseases
title_sort novel viral vectors in infectious diseases
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721250/
https://www.ncbi.nlm.nih.gov/pubmed/28869761
http://dx.doi.org/10.1111/imm.12829
work_keys_str_mv AT humphreysianr novelviralvectorsininfectiousdiseases
AT sebastiansarah novelviralvectorsininfectiousdiseases